Nyrada's NYR-BI03 Advances to Phase I Trials After Promising Preclinical Safety Results
Key Insights
Nyrada (search)'s lead candidate, NYR-BI03 (search), has completed critical safety studies and is set for Phase I clinical trials in late 2024, targeting neuroprotective and cardioprotective conditions.
Preclinical toxicology tests in rats and dogs demonstrated that NYR-BI03 (search) was well tolerated, supporting its safety profile for human trials.
NYR-BI03 (search) showed significant protection to brain tissue following stroke (search) and reduced heart damage by 86% in preclinical models of coronary ischaemia (search).
Nyrada (search) (ASX:NYR) is advancing its lead candidate, NYR-BI03 (search), into Phase I clinical trials slated for late 2024, following the successful completion of preclinical safety studies. NYR-BI03 is a small molecule therapy designed to address neuroprotective and cardioprotective conditions, including stroke (search) and traumatic brain injury (search).
The preclinical studies, which included 14-day toxicology tests in both rats and dogs, indicated that NYR-BI03 (search) was well tolerated. These findings have bolstered confidence in the drug's safety profile and will support Nyrada (search)’s submission to the Human Ethics Research Committee, a crucial regulatory step before initiating the Phase I trial. The upcoming Phase I study will primarily assess the safety and pharmacokinetics of NYR-BI03 in healthy volunteers, with initial results anticipated by mid-2025.
Preclinical Efficacy
Beyond safety, NYR-BI03 (search) has demonstrated promising efficacy in preclinical models. Notably, it offered significant protection to brain tissue following a stroke (search) and reduced heart damage by 86% in models of coronary ischaemia (search). These results suggest that NYR-BI03 could potentially be a significant advancement in both neuroprotection and cardiovascular health.
Potential Impact
Nyrada (search)’s progress with NYR-BI03 (search) represents a notable step forward in addressing unmet medical needs in both brain injury (search) and heart disease (search). These therapeutic areas represent significant market opportunities, given the prevalence and impact of these conditions.